Understanding how keratin 19 affects drug resistance in breast cancer
Official title: Characterizing Regulatory Mechanisms Underlying Drug Resistance in Breast Cancer Using Keratin 19
Funded at Catholic University of America · NIH-10358875 · Data updated 2026-11-12
This study is looking at how a protein called keratin 19 affects breast cancer cells' ability to resist certain treatments, with the goal of finding better ways to personalize therapy for patients with advanced estrogen receptor-positive breast cancer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Catholic University of America NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | June 2, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2022 |
| Award (this year) | $473,458 |
| NIH project number | 1R15CA267890-01 |
| Project ID | NIH-10358875 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced estrogen receptor-positive breast cancer who are being treated with CDK4/6 inhibitors.
✕Less likely to help
Patients with breast cancer who do not have estrogen receptor-positive tumors or are not receiving CDK4/6 inhibitors may not benefit from this research.
What this research studies
This research investigates the role of keratin 19, a cytoskeletal protein, in the resistance of breast cancer cells to CDK4/6 inhibitors, which are used to treat advanced estrogen receptor-positive tumors. The study aims to uncover the molecular mechanisms by which keratin 19 interacts with other proteins to influence cancer cell growth and drug sensitivity. By identifying how keratin 19 regulates these processes, the research seeks to develop predictive biomarkers that could help tailor more effective treatments for patients. The approach combines laboratory experiments with advanced biological assays to analyze the interactions and effects of keratin 19 in breast cancer cells.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for breast cancer patients by identifying biomarkers that predict drug resistance.
How similar studies have gone: Previous research has shown promising results in understanding drug resistance mechanisms in cancer, making this approach both relevant and potentially impactful.
Where this research is happening
-
Catholic University of America
Washington, United States Active
Researchers
- Principal investigator: Choy, John Sing — Catholic University of America
- Study coordinator: Choy, John Sing
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.